VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. have entered into a definitive agreement to combine in an all-stock transaction. Upon completion, the combined company will operate as Yarrow Bioscience, Inc. and will be listed on Nasdaq under the ticker symbol "YARW." The newly formed company will focus on advancing YB-101 (also known as GS-098), a clinical-stage TSHR antibody being developed for the treatment of Graves' disease $(GD)$ and thyroid eye disease (TED). Pre-closing private financings totaling approximately $200 million are expected to fund operations into 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603533) on December 17, 2025, and is solely responsible for the information contained therein.